Progress of oncolytic virus in treatment of gastric cancer / 肿瘤

ABSTRACT

China is a country with a high incidence of gastric cancer, ranking the top three in terms of morbidity and mortality. More than 70% of new patients with gastric cancer have been diagnosed at advanced stage. Traditional chemotherapy drugs have hit the plateau. In recent years, oncolytic virus, which specifically kills tumor cells, has developed rapidly. It is considered to have the characteristics of targeting tumor. A large number of viruses replicate in tumor cells, leading to cell lysis or inducing immune response by releasing virus molecules and cytokines further to fight against tumor. The genetically engineered strains of oncolytic virus have shown effective anti-tumor ability both in vivo and in vitro. Its safety and effectiveness have been proved in clinical practice. So the oncolytic virotherapy is expected to be a new direction and breakthrough point in the treatment of gastric cancer. This paper reviews the anti-tumor mechanism, the research progress of genetically engineered strains in the treatment of gastric cancer and the existing challenges of oncolytic virus.